Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Prostate Clear all

Conditions: Prostate Cancer
Interventions: Panobinostat; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more

Conditions: Prostate Cancer
Interventions: Doxil and Estramustine; Drug
Lead sponsor: Morton Plant Mease Health Care; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Prostate Cancer
Interventions: NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT; Drug
Lead sponsor: Nanobiotix; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Prostatic Neoplasms
Interventions: PROSTVAC-V/F; Biological
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years and older · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Prostate Cancer, High-Risk Localized Prostate Cancer, Locally Advanced Prostate Cancer, Low-Risk Prostate Cancer, Intermediate Risk Prostate Cancer
Interventions: PSMA PET, MRI, 18F-DCFPyL; Device · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Breast Cancer, Prostate Cancer, Body Composition, White Adipose Tissue Inflammation
Interventions: DEXA Scan, Godin Leisure Time Exercise Questionnaire (GLTEQ); Device · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 9
States / cities: Milford, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Prostate Cancer
Interventions: Etoposide, Cyclophosphamide; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 7
States / cities: East Brunswick, New Jersey • Hamilton, New Jersey • Morristown, New Jersey + 3 more

Conditions: Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
Interventions: NX-1607, Paclitaxel; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: Prostate Cancer
Interventions: zoledronate therapy, PET Scan; Drug · Device
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Detroit, Michigan • Farmington Hills, Michigan

Conditions: Neuroendocrine Prostate Cancer (NEPC), Metastatic Prostate Adenocarcinoma, Prostate Cancer
Interventions: Ifinatamab Deruxtecan, Positron Emission Tomography (PET)/Computerized Tomography (CT), Computerized Tomography (CT)/ Magnetic Resonance Imaging (MRI), Bone Scan, Blood Specimen Collection; Drug · Procedure
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer
Interventions: Walk with Ease; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 65 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Clinical Stage T2b or Less of Prostate Cancer, Prostate Brachytherapy, Transrectal Prostate Ultrasound Treatment Planning
Interventions: An ultrasound-based technique to identify prostate cancer, pre-implant transrectal ultrasound images and planning, ultrasound-based cancer-specific images; Other
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Carcinoma
Interventions: Shear Wave Elastography, Ultrasound Elasticity Imaging, Ultrasound-Guided Prostate Biopsy; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer, Cancer of the Prostate, Prostate Neoplasm
Interventions: CyberKnife Radiosurgery; Radiation
Lead sponsor: Community Cancer Center, Normal, Illinois; Other
Eligibility: 21 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: Normal, Illinois

Conditions: Prostate Cancer
Interventions: Pacritinib; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Prostate Cancer
Interventions: bicalutamide, estramustine, etoposide, flutamide, goserelin, leuprolide, nilutamide, paclitaxel; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 91
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more

Conditions: Breast Cancer, Prostate Cancer
Interventions: HER2 FPBMC; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Prostate Cancer
Interventions: Focal-Fusion Bx; Device
Lead sponsor: Focal Healthcare Inc.; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Sarasota, Florida

Conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Endometrial Cancer, History of Cancer
Interventions: Publicly available genetic testing resources, Virtual genetics navigator, Motivational interviewing (MI); Other · Behavioral
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 793 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Prostate Cancer (CRPC)
Interventions: Not listed
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: Hypofractionated Whole Pelvis Proton Therapy with Brachytherapy Boost; Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: Leuvectin; Biological
Lead sponsor: Vical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 2
States / cities: Los Angeles, California • Cleveland, Ohio

Conditions: Prostate Cancer
Interventions: Vitamin E, Selenium, Vitamin E placebo, selenium placebo; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 50 Years to 120 Years · Male only
Enrollment: 35,533 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2012
U.S. locations: 13
States / cities: Chicago, Illinois • Joliet, Illinois • Maywood, Illinois + 8 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: [225Ac]Ac-FL-020, Blood samples for PK, [111In]In-FL-020, Blood and urine samples collection, SPECT/CT images; Drug · Procedure
Lead sponsor: Full-Life Technologies UK Limited; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Duarte, California • Irvine, California • Stanford, California + 2 more

Search by objective public record fields.

Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy

PSMA PET/MRI for Predicting and Detecting Prostate Cancer

Body Composition and White Adipose Tissue Inflammation

Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer

A Study of NX-1607 in Adults With Advanced Malignancies

PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer

Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer

Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer

Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy

Ultrasound-Based Imaging Using the Aixplorer System in Diagnosing Prostate Cancer in Patients Undergoing Biopsy

A Phase II Trial of CyberKnife Stereotactic Radiosurgery to Prostate Tumors

Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

Targeted Prostate Biopsy Using a Novel MRI-Ultrasound Fusion Device

Michigan Genetic Hereditary Testing (MiGHT)

Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity

Hypofractionated WPPT With HDR Boost

Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer

S0000 Selenium and Vitamin E in Preventing Prostate Cancer

Study With [225Ac]Ac-FL-020 in mCRPC Participants